

PATENT

Attorney Docket No.: 014643-009020US
A-72013/GKS/THR(455675-77)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



re application of:

Examiner: Nolan, P.

LONBERG and KAY

Group Art Unit: 1644

Serial No.: 08/728,463

Filed: October 10, 1996

For: TRANSGENIC NON-HUMAN
ANIMALS FOR PRODUCING
HETEROLOGOUS ANTIBODIES

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed
enclosures, is being deposited with the United States Postal
Service as First Class Mail in an envelope addressed to:
Mail Stop RCE, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: November 24, 2003

By: Traci H. Ropp
Traci H. Ropp

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with
the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant wishes to draw the attention of the U.S.
Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A.
Copies of the references are enclosed.

None of the foregoing references are believed to disclose the invention as claimed.
Nothing herein shall constitute an admission concerning the contents of any of the cited
references, nor shall the inclusion of a reference herein be considered an admission that the
reference constitutes prior art against the invention claimed in the above-identified application.

12/03/2003 AMONDAF1 00000001 08728463

02 FC:1806

180.00 DP

1124622_1

Serial No. 10/000,433
Filing Date: November 30, 2001

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Pursuant to 37 C.F.R. §1.97(c), enclosed is a check in the amount of \$180.00 as set forth in 37 C.F.R. §1.17(p). While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 455675-077 (A-72013/GKS/THR)).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: Nov. 24, 2003
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

BY: Traci H. Ropp
Traci H. Ropp, Reg. No. 44,307

Filed under 37 C.F.R. § 1.34(a)

Attachments : Form PTO/SB/8A, Substitute for form 1449
8 cited references
Check for \$180.00

Substitute for form 1449B/PTO U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 014643-009020US A-72013 (455675-77)	APPLICATION NO.: 08/728,463
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		FIRST NAMED INVENTOR: LONBERG	
		FILING DATE: October 10, 1996	ART UNIT: 1644
Sheet	2	of	2
		EXAMINER NAME: Patrick J. Nolan	



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS ¹	Cite No. ¹	(Include name of Author) in CAPITAL LETTERS). Title of article (when appropriate, title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published)	T ²
	C102	SILBERSTEIN, L.E., et al., "Variable Region Gene Analysis of Pathologic Human Autoantibodies to the Related i and l Red Blood Cell Antigens," <i>Blood</i> , vol. 78, no. 9: 2372-2386 (1991).	
	C103	TAYLOR, L.D., et al., "A Transgenic Mouse That Expresses A Diversity of Human Sequence Heavy and Light Chain Immunoglobins," <i>Nucleic Acids Research</i> , vol. 20, no. 23: 6287-6295 (1992).	
	C104	TUAILLON, N., et al., "Human Immunoglobulin Heavy-Chain Minilocus Recombination in Transgenic Mice: Gene-Segment Use in Mu and Gamma Transcripts," <i>Proc. Nat. Acad. Sci. USA</i> , vol. 90: 3720-3724 (1993).	
EXAMINER SIGNATURE			DATE CONSIDERED

¹ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant

¹ Applicant's unique citation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.

PIPE JOINT
DEC 01 2003
PATENT & TRADEMARK
EXAM

[illegible]

EXAMINER INITIALS ⁵	Cite No. ¹	DOCUMENT NUMBER	PUBLICATION DATE	Name of PATENTEE or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)	MM-DD-YYYY			
	B6	WO 94 25585 A	11/10/1994	Genpharm Int.		
	B7	WO 93 12227 A	06/24/1993	Genpharm Int.		
	B8	WO 93 11794 A	06/24/1993	Xoma Corp.		
	B9	EP 0 592 106 A	04/13/1994	Immunogen Inc.		
	B10	WO 92 01047 A	01/23/1992	Cambridge Antibody Tech.		
EXAMINER SIGNATURE				DATE CONSIDERED		

include copy of this form with next communication to applicant.

¹ Applicant's unique citation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.